Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Adjusts Seagen Price Target to $178 From $181, Maintains Equalweight Rating

01/18/2022 | 01:03pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about SEAGEN INC.
05/23Seagen Sees Positive Topline Data From Study of Tukysa With Trastuzumab in HER2-Positiv..
MT
05/23SEAGEN : Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (..
PU
05/23SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® ..
BU
05/23Seagen Inc. Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUK..
CI
05/19SEAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16US Stocks Begin Week Mostly Lower Amid Empire State Manufacturing Weakness
MT
05/16US Stocks Begin Week Mostly Lower as First Manufacturing Data for May Turns Negative
MT
05/16Top Midday Gainers
MT
05/16INSIDER SELL : Seagen
MT
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 796 M - -
Net income 2022 -651 M - -
Net cash 2022 1 615 M - -
P/E ratio 2022 -38,1x
Yield 2022 -
Capitalization 24 569 M 24 569 M -
EV / Sales 2022 12,8x
EV / Sales 2023 9,12x
Nbr of Employees 2 675
Free-Float 99,2%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 133,47 $
Average target price 161,00 $
Spread / Average Target 20,6%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
David W. Gryska Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-13.67%25 649
MODERNA, INC.-48.00%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-28.41%38 497
ICON PUBLIC LIMITED COMPANY-30.17%17 688
CELLTRION, INC.-26.77%16 131